Oncolytics Biotech Inc.'s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
CALGARY, June 01, 2007 /PRNewswire-FirstCall/ - Research collaborators with Oncolytics Biotech Inc. ("Oncolytics") are scheduled to deliver a poster presentation covering REOLYSIN(R) clinical trial data at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2007 in Chicago. The data cover final results of Oncolytics' U.K. Phase I systemic administration trial.
The poster, entitled "Final Results of a Phase I Study of Wild-Type Oncolytic Reovirus Administered Intravenously to Patients with Advanced Cancer" is scheduled to be presented by Dr. James Spicer of The Royal Marsden Hospital and The Institute of Cancer Research, U.K. on Sunday, June 3, 2007.
The poster will be available on the Oncolytics website on Monday, June 4, 2007.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials to be presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.
CONTACT: Oncolytics Biotech Inc., Cathy Ward, 210, 1167 Kensington Cr NW,Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403) 283-0858,; The Equicom Group, Nick Hurst, 325, 300 5th Ave.SW, Calgary, Alberta, T2P 3C4, Tel: (403) 538-4845, Fax: (403) 237-6916,; The Investor Relations Group, Erika Moran, 11Stone St, 3rd Floor, New York, NY 10004, Tel: (212) 825-3210, Fax: (212)825-3229, firstname.lastname@example.org email@example.com firstname.lastname@example.org
Ticker Symbol: (Toronto:ONC.),(NASDAQ-NMS:ONCY)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: June 2007